SARS-CoV-2 (2019-nCoV) Spike S2 ECD-His Recombinant Protein

COVID-19 Spike S2 Research.
1/1
Price:
Size:
Number:

SARS-CoV-2 (2019-nCoV) Spike S2 ECD-His Recombinant Protein: 製品情報

純度
> 90 % as determined by SDS-PAGE.
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
活性
Testing in progress
タンパク質の構築
A DNA sequence encoding the SARS-CoV-2 (2019-nCoV) Spike Protein (S2 ECD) (YP_009724390.1) (Ser686-Pro1213) was expressed with a polyhistidine tag at the C-terminus.
発現ホスト
Baculovirus-Insect Cells
2019-nCoV
予測N末端
Ser 686
分子量
The recombinant SARS-CoV-2 (2019-nCoV) Spike Protein (S2 ECD, His tag) consists of 539 amino acids and predicts a molecular mass of 59.37 kDa.
バッファー
Lyophilized from sterile 20 mM PB, 300 mM NaCl, 10 % glycerol, pH 7.0.
Please contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
配送
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
安定性 & 保存条件
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
再構成
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

SARS-CoV-2 (2019-nCoV) Spike S2 ECD-His Recombinant Protein: 画像

SARS-CoV-2 (2019-nCoV) Spike S2 ECD-His Recombinant Protein: 別名

coronavirus spike Protein, 2019-nCoV; cov spike Protein, 2019-nCoV; ncov RBD Protein, 2019-nCoV; ncov s1 Protein, 2019-nCoV; ncov s2 Protein, 2019-nCoV; ncov spike Protein, 2019-nCoV; NCP-CoV RBD Protein, 2019-nCoV; NCP-CoV s1 Protein, 2019-nCoV; NCP-CoV s2 Protein, 2019-nCoV; NCP-CoV Spike Protein, 2019-nCoV; novel coronavirus RBD Protein, 2019-nCoV; novel coronavirus s1 Protein, 2019-nCoV; novel coronavirus s2 Protein, 2019-nCoV; novel coronavirus spike Protein, 2019-nCoV; RBD Protein, 2019-nCoV; S1 Protein, 2019-nCoV; S2 Protein, 2019-nCoV; Spike RBD Protein, 2019-nCoV

Coronavirus spike 背景情報

The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2; DPP4, dipeptidyl peptidase-4; APN, aminopeptidase N; CEACAM, carcinoembryonic antigen-related cell adhesion molecule 1; Sia, sialic acid; O-ac Sia, O-acetylated sialic acid. The spike is essential for both host specificity and viral infectivity. The term 'peplomer' is typically used to refer to a grouping of heterologous proteins on the virus surface that function together. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. It's been reported that SARS-CoV-2 (COVID-19 coronavirus, 2019-nCoV) can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. The main functions for the Spike protein are summarized as: Mediate receptor binding and membrane fusion; Defines the range of the hosts and specificity of the virus; Main component to bind with the neutralizing antibody; Key target for vaccine design; Can be transmitted between different hosts through gene recombination or mutation of the receptor binding domain (RBD), leading to a higher mortality rate.
参考文献
  • Shen S, et al. (2007) Expression, glycosylation, and modification of the spike (S) glycoprotein of SARS CoV. Methods Mol Biol. 379: 127-35.
  • Du L, et al. (2009) The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol. 7 (3): 226-36.
  • Xiao X, et al. (2004) The SARS-CoV S glycoprotein. Cell Mol Life Sci. 61 (19-20): 2428-30.

2019-nCoV Coronavirus spike タンパク質

  • Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Blood using a Coronavirus Antigen Microarray
    Author
    De Assis, RR;Jain, A;Nakajima, R;Jasinskas, A;
    Year
    2020
    Journal
    BioRxiv
  • Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray
    Author
    Khan, S;Nakajima, R;Jain, A;De Assis, RR;Jasinskas, A;
    Year
    2020
    Journal
    BioRxiv
  • Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections
    Author
    Lv, H;Wu, NC;Tsang, OTY;Yuan, M;Perera, RAPM;
    Year
    2020
    Journal
    bioRxiv
    Application
    ELISA
  • Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals
    Author
    Zhu, Y;Yu, D;Han, Y;Yan, H;Chong, H;Ren, L;Wang, J;
    Year
    2020
    Journal
    bioRxiv
  • Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein
    Author
    Feng, S;Luan, X;Wang, Y;Wang, H;Zhang, Z;Wang, Y;Tian, Z;Liu, M;Xiao, Y;Zhao, Y;Zhou, R;Zhang, S;
    Year
    2020
    Journal
    Infect. Genet. Evol.
  • Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 infection
    Author
    Simon, D;Tascilar, K;Krönk, G;Kleyer, A;Zaiss, M;Heppt, F;Meder, C;Atreya, R;Klenske, E;Dietrich, P;Abdullah, A;Kliem, T;Corte, G;Morf, H;Leppkes, M;Kremer, A;Ramming, A;Pachowsky, M;Schuch, F;Ronneberger, M;Kleinert, S;Maier, C;Hueber, A;Manger, K;Manger, B;Berking, C;Tenbusch, M;Überla, K;Sticherling, M;Neurath, M;Schett, G;
    Year
    2020
    Journal
    Research Square
  • Array-based analysis of SARS-CoV-2, other coronaviruses, and influenza antibodies in convalescent COVID-19 patients
    Author
    Steiner, D;Cognetti, J;Luta, E;Klose, A;Bucukovski, J;Bryan, M;Schmuke, J;Nguyen-Contant, P;Sangster, M;Topham, D;Miller, B;
    Year
    2020
    Journal
    bioRxiv
  • Cross-reactivity of neutralizing antibody and its correlation with circulating T follicular cells in recovered COVID-19 individuals
    Author
    Zhang, J;Qu, X;
    Year
    2020
    Journal
    medRxiv
  • A rapidly adaptable biomaterial vaccine for SARS-CoV-2
    Author
    Langellotto, F;Seiler, B;Yu, J;Cartwright, M;White, D;Yeager, C;Super, M;Doherty, E;Barouch, D;Mooney, D;
    Year
    2020
    Journal
    bioRxiv
カートに追加しました カートに追加しませんでした カートを更新しています。少々お待ちください U.S.A.